Discontinued — last reported Q2 '21
Current Assets
Restricted Cash
Vertex Pharmaceuticals Restricted Cash decreased by 16.3% to $8.20M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 7.9%, from $8.90M to $8.20M. Over 4 years (FY 2020 to FY 2024), Restricted Cash shows an upward trend with a 38.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ1 2019
Last reportedQ2 2021
How to read this metric
An increase suggests higher regulatory or contractual obligations, potentially reducing operational liquidity, while a decrease may indicate the release of restricted funds.
Detailed definition
Cash balances that are legally or contractually restricted from being used for general corporate purposes. This often in...
Peer comparison
Standard line item for all major banks; peers disclose this to clarify the portion of cash that is not immediately available for deployment.
Metric ID:
restricted_cashHistorical Data
17 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.50M | $5.10M | $3.90M | $1.90M | $5.50M | $8.00M | $5.70M | $2.30M | $6.40M | $3.20M | $11.40M | $10.90M | $8.90M | $2.60M | $10.70M | $9.80M | $8.20M |
| QoQ Change | — | +13.3% | -23.5% | -51.3% | +189.5% | +45.5% | -28.7% | -59.6% | +178.3% | -50.0% | +256.3% | -4.4% | -18.3% | -70.8% | +311.5% | -8.4% | -16.3% |
| YoY Change | — | — | — | — | +22.2% | +56.9% | +46.2% | +21.1% | +16.4% | -60.0% | +100.0% | +373.9% | +39.1% | -18.8% | -6.1% | -10.1% | -7.9% |
Range$1.90M – $11.40M
CAGR+16.2%
Avg YoY Growth+44.1%
Median YoY Growth+21.1%
Current Streak2 quarters decline
Restricted Cash at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's restricted cash?
- Vertex Pharmaceuticals (VRTX) reported restricted cash of $8.20M in Q3 2025.
- How has Vertex Pharmaceuticals's restricted cash changed year-over-year?
- Vertex Pharmaceuticals's restricted cash decreased by 7.9% year-over-year, from $8.90M to $8.20M.
- What is the long-term trend for Vertex Pharmaceuticals's restricted cash?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's restricted cash has grown at a 38.8% compound annual growth rate (CAGR), from $700.00K to $2.60M.
- What does restricted cash mean?
- Cash that is set aside for specific purposes and cannot be used for general business needs.